Investigators at the University of Cincinnati have found a safe and effective treatment for life-threatening angioedema attacks in the emergency department.
In angioedema, patients experience a rapid swelling of the skin and subcutaneous tissues—which, in some cases, can lead to airway obstruction and suffocation. Physicians usually treat angioedema like an allergic reaction with corticosteroids and antihistamines.
But that therapy doesn’t always work for another version of the condition, thought to be caused by taking a class of drugs known as ACE inhibitors.
"ACE inhibitors are a common treatment in patients with congestive heart failure and hypertension,” says Joseph Moellman, MD, associate professor of emergency medicine. "It is also the most common etiology of patients presenting to the emergency department with angioedema.”
Moellman says there’s currently no treatment for ACE inhibitor induced (ACEI) angioedema, as the physiology of the condition is different—caused by the levels of the blood vessel-dilating peptide bradykinin in the body.
In a triple blind, placebo-controlled phase-2 trial, Moellman worked with professor of medicine and angioedema expert Jonathan Bernstein, MD, and fellow researchers at the UC Medical Center Emergency Department to study the drug Ecallantide in the treatment of ACEI angioedema that failed to respond to the conventional therapy of corticosteroids and antihistamines.
They wanted to see if Ecallantide, which has already safely treated acute attacks of hereditary angioedema, could help patients with ACEI angioedema—specifically, if it could make them eligible for discharge within four hours of treatment.
After enrolling 50 patients in the study, they found that patients treated with Ecallantide were more likely to meet discharge sooner than those receiving antihistamines and steroids—31 percent of Ecallantide patients were eligible for discharge within four hours, as compared with 21 percent of patients receiving placebos. Additionally, patients experienced few side effects from the medication.
Moellman says the data supports launching a phase-3 trial, which will enroll more patients to confirm the initial results. He is presenting the results at the annual meeting of the Society for Academic Emergency Medicine, held May 14-17 in Dallas.
Co-authors of the study include Christopher Lindsell, PhD, Kimberly Hart and Sean Collins, MD. The study was funded by Dyax, manufacturer of Ecallantide, or Kalibtor. Bernstein is a consultant and speaker for Dyax.
Kathryn Cosse | Eurek Alert!
The healing effect of radon
23.01.2019 | Friedrich-Alexander-Universität Erlangen-Nürnberg
Energizing the immune system to eat cancer
22.01.2019 | University of Pennsylvania School of Medicine
So-called bifacial stem cells are responsible for one of the most critical growth processes on Earth – the formation of wood.
Immune cells called macrophages are supposed to serve and protect, but cancer has found ways to put them to sleep. Now researchers at the Abramson Cancer...
The scientific and political community alike stress the importance of German Antarctic research
Joint Press Release from the BMBF and AWI
The Antarctic is a frigid continent south of the Antarctic Circle, where researchers are the only inhabitants. Despite the hostile conditions, here the Alfred...
World first experiments on sensor that may revolutionise everything from medical devices to unmanned vehicles
The new sensor - capable of detecting vibrations of living cells - may revolutionise everything from medical devices to unmanned vehicles.
Dead and alive at the same time? Researchers at the Max Planck Institute of Quantum Optics have implemented Erwin Schrödinger’s paradoxical gedanken experiment employing an entangled atom-light state.
In 1935 Erwin Schrödinger formulated a thought experiment designed to capture the paradoxical nature of quantum physics. The crucial element of this gedanken...
16.01.2019 | Event News
14.01.2019 | Event News
12.12.2018 | Event News
23.01.2019 | Physics and Astronomy
23.01.2019 | Materials Sciences
23.01.2019 | Life Sciences